Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.

Background: Glioblastoma is a highly malignant disease with limited treatment options. Ibrutinib, a covalent Bruton tyrosine kinase inhibitor, is an oral agent with manageable side effects used for hematological diseases including Waldenström macroglobulinemia. We present the case of a 69-year-old Caucasian male patient treated with ibrutinib for suspected Bing-Neel syndrome (BNS), which following a biopsy, was reclassified as glioblastoma.

The use of olfactory testing when diagnosing Parkinson's disease - a systematic review.

Introduction: The diagnosis of Parkinson's disease (PD) is typically based on the presence of motor symptoms, but in the early phase of the disease, the diagnostic process can be challenging. Examination of non-motor symptoms in patients suspected of PD has gained growing attention. Olfactory tests have shown promising results as ancillary diagnostic tests.